Perfect use versus typical use: translating outcomes in the treatment of diabetic macular oedema

摘要: Diabetic macular oedema (DMO) is a major cause of visual impairment in working age adults, and is the most prevalent vision-threatening form of diabetic retinopathy (DR)[1]. It is estimated that 5.5 million people in the United Kingdom will have diabetes by 2030, highlighting the significant health and economic burden of this condition [2]. Over the last decade, there has been a paradigm shift in the management of patients with DMO. Intravitreal anti-vascular endothelial growth factor therapy (anti-VEGF) is now considered the mainstay of treatment, with landmark trials establishing its efficacy with mean visual gains of between+ 9.7 and+ 13.3 letters at 1 year [3–6]. Currently there are two main anti-VEGF therapy in use for DMO in the UK: ranibizumab, which was approved by the National Institute of Health and Care Excellence (NICE) in 2013 [7], and aflibercept, which was approved in 2015 [8]. A third VEGF inhibitor …